Abstract
The story of antimalarials as antinflammatory drugs dates back several centuries. Chinin, the extract of the Cinchona bark, has been exploited since the 18th century for its antimalarial and antifebrile properties. Later, during the Second World War, the broad use of antimalarials allowed arguing their antirheumatic effect on soldiers. Since then, these drugs have been broadly used to treat Systemic Lupus Erythematosus, but, only recently, have the molecular mechanisms of action been partly clarified.
Inhibitory action on vacuole function and trafficking has been considered for decades the main mechanism of the action of antimalarials, affecting the activation of phagocytes and dendritic cells. In addition, chloroquine is also known as a potent inhibitor of autophagy, providing another possible explanation of its antinflammatory action. However, much attention has been recently devoted to the action of antimalarials on the so-called cGASSTING pathway leading from the sensing of cytoplasmic nucleic acids to the production of type I interferons.
This pathway is a fundamental mechanism of host defence, since it is able to detect microbial DNA and induce the type I interferon-mediated immune response. Of note, genetic defects in the degradation of nucleic acids lead to inappropriate cGAS-STING activation and inflammation. These disorders, called type I interferonopathies, represent a valuable model to study the antinflammatory potential of antimalarials.
We will discuss possible development of antimalarials to improve the treatment of type I interferonopathies and likely multifactorial disorders characterised by interferon inflammation, such as Systemic Lupus Erythematosus.
Keywords: Antimalarials, Autoimmunity, Autoinflammatory diseases, Interferonopathies, Interferon Signature, Cyclic GMP-AMP Synthase, Systemic Lupus Erythematosus, Type I Interferons.
Current Medicinal Chemistry
Title:Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Volume: 25 Issue: 24
Author(s): Elisa Piscianz, Eva Cuzzoni, Rajan Sharma, Alessandra Tesser, Pooja Sapra and Alberto Tommasini*
Affiliation:
- Department of Paediatrics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste,Italy
Keywords: Antimalarials, Autoimmunity, Autoinflammatory diseases, Interferonopathies, Interferon Signature, Cyclic GMP-AMP Synthase, Systemic Lupus Erythematosus, Type I Interferons.
Abstract: The story of antimalarials as antinflammatory drugs dates back several centuries. Chinin, the extract of the Cinchona bark, has been exploited since the 18th century for its antimalarial and antifebrile properties. Later, during the Second World War, the broad use of antimalarials allowed arguing their antirheumatic effect on soldiers. Since then, these drugs have been broadly used to treat Systemic Lupus Erythematosus, but, only recently, have the molecular mechanisms of action been partly clarified.
Inhibitory action on vacuole function and trafficking has been considered for decades the main mechanism of the action of antimalarials, affecting the activation of phagocytes and dendritic cells. In addition, chloroquine is also known as a potent inhibitor of autophagy, providing another possible explanation of its antinflammatory action. However, much attention has been recently devoted to the action of antimalarials on the so-called cGASSTING pathway leading from the sensing of cytoplasmic nucleic acids to the production of type I interferons.
This pathway is a fundamental mechanism of host defence, since it is able to detect microbial DNA and induce the type I interferon-mediated immune response. Of note, genetic defects in the degradation of nucleic acids lead to inappropriate cGAS-STING activation and inflammation. These disorders, called type I interferonopathies, represent a valuable model to study the antinflammatory potential of antimalarials.
We will discuss possible development of antimalarials to improve the treatment of type I interferonopathies and likely multifactorial disorders characterised by interferon inflammation, such as Systemic Lupus Erythematosus.
Export Options
About this article
Cite this article as:
Piscianz Elisa , Cuzzoni Eva , Sharma Rajan , Tesser Alessandra , Sapra Pooja and Tommasini Alberto *, Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs, Current Medicinal Chemistry 2018; 25 (24) . https://dx.doi.org/10.2174/0929867324666170911162331
DOI https://dx.doi.org/10.2174/0929867324666170911162331 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents Related to Pathogenic Human Coronaviruses
Recent Patents on Biotechnology The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Specific Nutritional Needs for Children: Are Children Small Adults?
Current Pediatric Reviews Strategies for Antimicrobial Drug Delivery to Biofilm
Current Pharmaceutical Design Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload
Infectious Disorders - Drug Targets Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Bone Marrow Reconstitution as a Relevant Model of Genetically Programmed Leukemia
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design